{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:28:51Z","timestamp":1786325331491,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117084","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:23:07Z","timestamp":1782858187000},"page":"117084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An engineered oncolytic vaccinia virus expressing PD-L1 inhibitor exerts anti-tumor effects on glioblastoma by activating T cell responses"],"prefix":"10.1016","volume":"186","author":[{"given":"Xin","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.intimp.2026.117084_bb0005","doi-asserted-by":"crossref","first-page":"13367","DOI":"10.3390\/ijms241713367","article-title":"High Thioredoxin domain-containing protein 11 expression is associated with tumour progression in glioma","volume":"24","author":"Chen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117084_bb0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.neuroscience.2024.09.022","article-title":"Contemporary strategies in glioblastoma therapy: recent developments and innovations","volume":"560","author":"Khan","year":"2024","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.intimp.2026.117084_bb0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s40478-020-01078-2","article-title":"TERT promoter mutation confers favorable prognosis regardless of 1p\/19q status in adult diffuse gliomas with IDH1\/2 mutations","volume":"8","author":"Arita","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2026.117084_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of glioblastoma multiforme-literature review","volume":"14","author":"Grochans","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117084_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.mie.2019.05.032","article-title":"Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models","volume":"631","author":"Alghamri","year":"2020","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.intimp.2026.117084_bb0030","doi-asserted-by":"crossref","unstructured":"Zhang, Y.; Yang, X.; Zhu, X. L.; Hao, J. Q.; Bai, H.; Xiao, Y. C.; Wang, Z. Z.; Hao, C. Y.; Duan, H. B., Bioinformatics analysis of potential core genes for glioblastoma. Biosci. Rep. 2020, 40 (7), BSR20201625.","DOI":"10.1042\/BSR20201625"},{"issue":"11","key":"10.1016\/j.intimp.2026.117084_bb0035","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/neuonc\/nox184","article-title":"Meeting update\u2014world Federation of Neuro-Oncology Societies (WFNOS) meeting 2017","volume":"19","author":"Renfrow","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"13","key":"10.1016\/j.intimp.2026.117084_bb0040","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.3390\/ijms23137207","article-title":"Glioblastoma treatment: state-of-the-art and future perspectives","volume":"23","author":"Rodr\u00edguez-Camacho","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117084_bb0045","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3332\/ecancer.2021.1176","article-title":"Therapeutic strategies of recurrent glioblastoma and its molecular pathways \u2018lock up the beast\u2019","volume":"15","author":"El-Khayat","year":"2021","journal-title":"Ecancermedicalscience"},{"issue":"12","key":"10.1016\/j.intimp.2026.117084_bb0050","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2026.117084_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"15","key":"10.1016\/j.intimp.2026.117084_bb0060","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.3390\/cancers13153721","article-title":"Immunotherapy in glioblastoma: a clinical perspective","volume":"13","author":"Desbaillets","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.intimp.2026.117084_bb0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cei.13403","article-title":"Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma","volume":"200","author":"Close","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"14","key":"10.1016\/j.intimp.2026.117084_bb0070","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2026.117084_bb0075","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2326-6066.CIR-14-0220-T","article-title":"Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor","volume":"3","author":"T\u00e4htinen","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117084_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006374","article-title":"OncoVEX(mGM-CSF)expands tumor antigen-specific CD8+ T-cell response in preclinical models","volume":"11","author":"Estrada","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117084_bb0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2017.00555","article-title":"Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives","volume":"8","author":"Guo","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117084_bb0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fonc.2014.00188","article-title":"Oncolytic viruses as anticancer vaccines","volume":"4","author":"Woller","year":"2014","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117084_bb0095","first-page":"646","article-title":"Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review","volume":"20","author":"Li","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.intimp.2026.117084_bb0100","doi-asserted-by":"crossref","first-page":"1594621","DOI":"10.3389\/fonc.2025.1594621","article-title":"Advances of oncolytic vaccinia viruses armed with interleukin in tumor therapy","volume":"15","author":"Zha","year":"2025","journal-title":"Front. Oncol."},{"issue":"24","key":"10.1016\/j.intimp.2026.117084_bb0105","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.117084_bb0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","article-title":"Oncolytic viruses and immune checkpoint inhibition: the best of both worlds","volume":"13","author":"Sivanandam","year":"2019","journal-title":"Molecular therapy oncolytics"},{"key":"10.1016\/j.intimp.2026.117084_bb0115","doi-asserted-by":"crossref","first-page":"1610858","DOI":"10.3389\/fimmu.2025.1610858","article-title":"Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms","volume":"16","author":"Cheng","year":"2025","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2026.117084_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14164023","article-title":"Next steps for immunotherapy in glioblastoma","volume":"14","author":"Cao","year":"2022","journal-title":"Cancers"},{"issue":"422","key":"10.1016\/j.intimp.2026.117084_bb0125","doi-asserted-by":"crossref","first-page":"eaam7577","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117084_bb0130","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2026.117084_bb0135","first-page":"493","article-title":"Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment","volume":"19","author":"Hardcastle","year":"2017","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117084_bb0140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/biomedicines13010098","article-title":"Advances in cell and immune therapies for melanoma","volume":"13","author":"Timis","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2026.117084_bb0145","doi-asserted-by":"crossref","first-page":"1170042","DOI":"10.3389\/fimmu.2023.1170042","article-title":"Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody","volume":"14","author":"Harwardt","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117084_bb0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.cr.7310017","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know","volume":"16","author":"Shi","year":"2006","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117084_bb0155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cgt.7700075","article-title":"Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant","volume":"7","author":"Puhlmann","year":"2000","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117084_bb0160","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2026.117084_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007633","article-title":"Central memory CD8+ T cells become CD69+ tissue-residents during viral skin infection independent of CD62L-mediated lymph node surveillance","volume":"15","author":"Osborn","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2026.117084_bb0170","series-title":"The Oncolytic Virus of p53-Armed NDV, in Combination with GM-CSF and iPD-L1, Induces the Immunogenic Cell Death of Melanoma","author":"Chen","year":"2025"},{"issue":"1","key":"10.1016\/j.intimp.2026.117084_bb0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117084_bb0180","doi-asserted-by":"crossref","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.intimp.2026.117084_bb0185","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2026.117084_bb0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117084_bb0195","first-page":"889","article-title":"Smallpox vaccine: contraindications, administration, and adverse reactions","volume":"68","author":"Maurer","year":"2003","journal-title":"Am. Fam. Physician"},{"issue":"12","key":"10.1016\/j.intimp.2026.117084_bb0200","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/2326-6066.CIR-21-0031","article-title":"Conditional PD-1\/PD-L1 Probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti-PD-1\/PD-L1 agents","volume":"9","author":"Assi","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.117084_bb0205","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.cell.2025.12.055","article-title":"Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial","volume":"189","author":"Meylan","year":"2026","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.intimp.2026.117084_bb0210","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00262-025-04139-4","article-title":"BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy","volume":"74","author":"Park","year":"2025","journal-title":"Cancer immunology, immunotherapy\u202f: CII"},{"issue":"3","key":"10.1016\/j.intimp.2026.117084_bb0215","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.3390\/ijms24033029","article-title":"How the innate immune DNA sensing cGAS-STING pathway is involved in apoptosis","volume":"24","author":"Zheng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117084_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emm.1998.1","article-title":"Cytokine regulation of expression of class I MHC antigens","volume":"30","author":"Raval","year":"1998","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117084_bb0225","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1523-1755.2004.00781.x","article-title":"Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients","volume":"66","author":"Verkade","year":"2004","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.intimp.2026.117084_bb0230","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3171\/2021.11.FOCUS21556","article-title":"Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes","volume":"52","author":"Letchuman","year":"2022","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.intimp.2026.117084_bb0235","doi-asserted-by":"crossref","first-page":"1583044","DOI":"10.3389\/fimmu.2025.1583044","article-title":"Mechanistic insights into resistance mechanisms to T cell engagers","volume":"16","author":"Cao","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117084_bb0240","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926009306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926009306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:42:18Z","timestamp":1786322538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926009306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"alternative-id":["S1567576926009306"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117084","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An engineered oncolytic vaccinia virus expressing PD-L1 inhibitor exerts anti-tumor effects on glioblastoma by activating T cell responses","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117084"}}